Nuvation Bio (NUVB) Long-Term Deferred Tax: 2020-2024

Nuvation Bio's Long-Term Deferred Tax was N/A to $154,000 in Q3 2020 from the same period last year, while for Sep 2020 it was $154,000, marking a year-over-year change of. This contributed to the annual value of $242.6 million for FY2024, which is 139.21% up from last year.
Nuvation Bio's Long-Term Deferred Tax amounted to $154,000 in Q3 2020.
In the past 5 years, Nuvation Bio's Long-Term Deferred Tax ranged from a high of $154,000 in Q3 2020 and a low of $154,000 during Q3 2020.
For the 1-year period, Nuvation Bio's Long-Term Deferred Tax averaged around $154,000, with its median value being $154,000 (2020).

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Deferred Tax (Qtr)
1	Summit Therapeutics Inc.	1,387.71B	1,387.50B	-	-
2	BeOne Medicines Ltd.	458.68B	457.16B	1.15B	-
3	Vertex Pharmaceuticals Inc / Ma	102.37B	99.35B	-	2.71B
4	Benitec Biopharma Inc.	65.38B	65.31B	-	-
5	Regeneron Pharmaceuticals, Inc.	60.67B	60.28B	-	3.57B
6	Alnylam Pharmaceuticals, Inc.	60.53B	62.66B	-	104.36M
7	Argenx Se	45.96B	50.00B	-	899.61M
8	INSMED Inc	26.50B	27.40B	-	-
9	BioNTech SE	25.15B	17.24B	-	76.46M
10	Nuvation Bio Inc.	1.42B	1.38B	2.26M	-